ROSELAND, N.J. - Milestone Scientific Inc. (NYSE:MLSS), a developer of advanced drug delivery instruments, has initiated sales of its CompuFlo Epidural disposables to Omaha Pain Physicians, a Nebraska-based pain management center. This development follows a successful trial by the clinic's medical director, Dr. Matthew Stottle, who reported a 100% success rate in 10 cases using the system.
The CompuFlo Epidural system is designed to enhance the safety and precision of Epidural Steroid Injection (ESI) procedures. Dr. Stottle, with over a decade of experience in pain medicine, emphasized the system's significant safety enhancements during ESIs. His endorsement reflects a commitment to integrating new technologies for improved patient outcomes.
Milestone Scientific's CEO, Arjan Haverhals, expressed satisfaction with the adoption of their technology by another pain clinic. He noted that the successful evaluation at Omaha Pain Physicians continues to demonstrate the CompuFlo system's safety and effectiveness. The company anticipates that such clinical adoptions will support its efforts in securing reimbursement approvals.
Milestone Scientific specializes in the development of injection technologies for medical, dental, and cosmetic applications. Their proprietary DPS Dynamic Pressure Sensing Technology® aims to improve injection precision and patient comfort.
This announcement is based on a press release statement from Milestone Scientific Inc.
InvestingPro Insights
In light of Milestone Scientific Inc.'s (NYSE:MLSS) recent announcement of the successful adoption of their CompuFlo Epidural system by Omaha Pain Physicians, investors may consider the financial health and market position of the company as part of their assessment. According to the latest data from InvestingPro, Milestone Scientific has a market capitalization of approximately $53.38 million USD, reflecting its size within the medical technology industry.
While the company's innovative technology is gaining clinical traction, an InvestingPro Tip reveals that analysts do not expect the company to be profitable this year, which is consistent with the reported operating income margin for the last twelve months as of Q1 2023 being a negative 72.82%. However, another InvestingPro Tip suggests that the company's liquid assets exceed short-term obligations, which may provide some financial flexibility in the near term.
From a valuation standpoint, Milestone Scientific is trading at a high Price / Book multiple of 7.36, based on the last twelve months as of Q1 2023. This could indicate that the market has optimistic expectations for the company's future growth or its technology's potential. Additionally, the company does not pay dividends, which is typical for firms focused on reinvesting profits into growth and development.
For investors seeking a deeper analysis, there are additional InvestingPro Tips available for MLSS, which can be found at https://www.investing.com/pro/MLSS. To enhance your investing strategy, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and unlock the full spectrum of insights on InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.